<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04948411</url>
  </required_header>
  <id_info>
    <org_study_id>LACOG 0120</org_study_id>
    <nct_id>NCT04948411</nct_id>
  </id_info>
  <brief_title>Durvalumab as Maintenance in Patients Who Received Chemoradiotherapy for Unresectable Stage III NSCLC: Real World Data From an Expanded Access Program in Brazil</brief_title>
  <acronym>EAP DURVA LUNG</acronym>
  <official_title>Durvalumab as Maintenance in Patients Who Received Chemoradiotherapy for Unresectable Stage III NSCLC: Real World Data From an Expanded Access Program in Brazil.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Latin American Cooperative Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Latin American Cooperative Oncology Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Durvalumab as maintenance in patients who received chemoradiotherapy for unresectable stage&#xD;
      III NSCLC: Real World Data from an Expanded Access Program in Brazil&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 30, 2021</start_date>
  <completion_date type="Anticipated">January 2024</completion_date>
  <primary_completion_date type="Anticipated">October 2023</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <target_duration>3 Years</target_duration>
  <primary_outcome>
    <measure>Describe real world data on PFS of patients treated with Durvalumab in stage III NSCLC in the EAP in Brazil</measure>
    <time_frame>June of 2018</time_frame>
  </primary_outcome>
  <other_outcome>
    <measure>- To describe Overall response rate, defined as the proportion of patients who have a partial or complete response to durvalumab therapy.</measure>
    <time_frame>June of 2018</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>- To describe Overall survival at 3 years, defined as the time from start of durvalumab therapy to death from any cause.</measure>
    <time_frame>June of 2018</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>- To describe the sequence of lines of treatment in patients which have disease progression after durvalumab.</measure>
    <time_frame>June of 2018</time_frame>
  </other_outcome>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <eligibility>
    <study_pop>
      <textblock>
        The study will include patients who have participated in the Durvalumab EAP in Brazil and&#xD;
        have received at least 1 dose of Durvalumab.&#xD;
&#xD;
        To enter the EAP, patients with unresectable stage III NSCLC must have completed a&#xD;
        platinum-based chemotherapy concurrently or sequentially with radiation therapy without&#xD;
        evidence of disease progression. It was preferred that treatment had started within&#xD;
        approximately three months from end of radiation for patients to recover from&#xD;
        treatment-related toxicities and/or for treating physicians to have adequate time to&#xD;
        perform the baseline disease assessment. There was no fixed maximum duration for Durvalumab&#xD;
        treatment. Treatment with Durvalumab continues until the physician determines its benefit&#xD;
        for the patient.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with unresectable stage III NSCLC who completed a platinum-based chemotherapy&#xD;
             concurrently or sequentially with radiation therapy without evidence of disease&#xD;
             progression&#xD;
&#xD;
          2. Patients who have participated in the Durvalumab EAP in Brazil and have received at&#xD;
             least one dose of Durvalumab in the EAP..&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mauro Zukin, MD</last_name>
    <phone>55 21 2986-3232</phone>
    <email>zukin.mauro@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ana Gelatti, MD</last_name>
    <phone>55 51 3230-2507</phone>
    <email>anagelatti@yahoo.com.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Núcleo de Oncologia da Bahia S.A</name>
      <address>
        <city>Salvador</city>
        <state>Bahia</state>
        <zip>41810-011</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Clarissa Maria de Cerqueira Mathias, MD</last_name>
      <phone>7140097085</phone>
      <email>pesquisaclinica@nob-ba.com.br</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto Mário Penna</name>
      <address>
        <city>Belo Horizonte</city>
        <state>Minas Gerais</state>
        <zip>30380-420</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ellias Magalhães e Abreu Lima, MD</last_name>
      <phone>55 31 33309100</phone>
      <email>ellias_lima@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>BP - A Beneficência Portuguesa de São Paulo</name>
      <address>
        <city>São Paulo</city>
        <zip>01323-001</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>William NASSIB WILLIAM JUNIOR, MD</last_name>
      <phone>1135055021</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sociedade Beneficente de Senhoras Hospital Sírio-Libanês</name>
      <address>
        <city>São Paulo</city>
        <zip>01409-003</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Kazumi Shimada, MD</last_name>
      <phone>1133944751</phone>
      <email>PESQUISA@HSL.ORG.BR</email>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <reference>
    <citation>Postmus PE, Kerr KM, Oudkerk M, Senan S, Waller DA, Vansteenkiste J, Escriu C, Peters S; ESMO Guidelines Committee. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017 Jul 1;28(suppl_4):iv1-iv21. doi: 10.1093/annonc/mdx222.</citation>
    <PMID>28881918</PMID>
  </reference>
  <reference>
    <citation>Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Yokoi T, Chiappori A, Lee KH, de Wit M, Cho BC, Bourhaba M, Quantin X, Tokito T, Mekhail T, Planchard D, Kim YC, Karapetis CS, Hiret S, Ostoros G, Kubota K, Gray JE, Paz-Ares L, de Castro Carpeño J, Wadsworth C, Melillo G, Jiang H, Huang Y, Dennis PA, Özgüroğlu M; PACIFIC Investigators. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med. 2017 Nov 16;377(20):1919-1929. doi: 10.1056/NEJMoa1709937. Epub 2017 Sep 8.</citation>
    <PMID>28885881</PMID>
  </reference>
  <reference>
    <citation>De Ruysscher D, Botterweck A, Dirx M, Pijls-Johannesma M, Wanders R, Hochstenbag M, Dingemans AM, Bootsma G, Geraedts W, Simons J, Pitz C, Lambin P. Eligibility for concurrent chemotherapy and radiotherapy of locally advanced lung cancer patients: a prospective, population-based study. Ann Oncol. 2009 Jan;20(1):98-102. doi: 10.1093/annonc/mdn559. Epub 2008 Aug 20.</citation>
    <PMID>18718891</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 24, 2021</study_first_submitted>
  <study_first_submitted_qc>June 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2021</study_first_posted>
  <last_update_submitted>October 5, 2021</last_update_submitted>
  <last_update_submitted_qc>October 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Carcinoma, Non-Small-Cell Lung</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

